There are currently 44 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Brain Metastases participants are Michigan, California, New York and North Carolina.
Neurocognitive Decline in Patients With Brain Metastases
NCT03508752
Recruiting
The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Brain Metastases
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +84 locations
Conditions: Brain Metastases
Register for Updates
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04923542
Recruiting
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Brain Metastases, HR+ Metastatic Breast Cancer
Register for Updates
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
NCT05673928
Recruiting
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Solid Tumor, Brain Metastases
Register for Updates
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
NCT06209567
Recruiting
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: High-grade Glioma, Brain Metastases, Brain Metastases, Adult
Register for Updates
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
NCT05323955
Recruiting
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should con... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of California San Francisco, San Francisco, California +7 locations
Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Register for Updates
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
NCT04246879
Recruiting
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Brain Metastases
Register for Updates
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04955743
Recruiting
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Register for Updates
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
NCT05700721
Recruiting
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
Register for Updates
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
NCT05559853
Recruiting
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Register for Updates
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
NCT05419076
Recruiting
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Hartford Healthcare (Data Collection Only), Hartford, Connecticut +7 locations
Conditions: Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048
Recruiting
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Brain Metastases, Adult, Brain Metastases, Brain Cancer
Register for Updates